TORONTO--(BUSINESS WIRE)--Kyto Biopharma Inc. (OTCBB: KBPH), is a biotechnology company focused on developing monoclonal antibody and oligonucleotide targeting therapeutics based on a proprietary vitamin B12 platform for the treatment of various forms of cancer.